Stem cell mediated treg activation/expansion for therapeutic immune modulation
Disclosed are cells, methods of modulating cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. Immune modulation including alteration of cytokine profile, cytotoxic activity, antibody production and inflammatory states is achieved through the administration of various cell types that have been unmanipulated or manipulated in order to endow specific biological activity. Cellular subsets and administration of the subsets in combination with various agents are also provided. One embodiment teaches the previously unknown finding that adipose tissue derived mononuclear cells contain T cells with immune regulatory properties that alone or synergistically with various stem cells induce immune modulation upon administration. Another embodiment is the finding that stimulation of stem cell activation results in stem cell secondary activation of immune modulatory cells, one type which is T regulatory cells (Tregs). One specific embodiment involves extraction of a heterogenous stem cell pool, which contains T regulatory cells, treatment in culture of the population with agents known to stimulate stem cell activation, then subsequent extraction and administration of the purified Tregs. Other embodiments include expansion of Tregs in the presence of antigen in order to generate anti-specific Tregs.
1. A method of immune modulation in a patient comprising the steps of:
a) selecting a patient in need of immune modulation; and
b) administering a therapeutically effective amount of adipose derived mononuclear T regulatory cells having enhanced immune modulatory activity compared to said mononuclear cells in a substantially unpurified state.
2. The method of claim 1 , wherein said adipose derived mononuclear cells are autologous such that they are derived from the patient in need.
3. The method of claim 1 , wherein said adipose derived mononuclear cells are subjected to a culturing step, said culturing step comprising of exposure to an agent or plurality of agents capable of augmenting immune regulatory ability of said adipose derived mononuclear cells.
4. The method of claim 1 , wherein a compound or plurality of compounds are administered prior to, concurrently with, or subsequently to administration of said adipose derived mononuclear cells in order to augment immune regulatory activity.
5. The method of claim 1 , wherein said adipose derived mononuclear cells are autologous and have a higher immune modulatory activity compared to autologous mononuclear cells derived from peripheral blood.
6. A method of immune modulation comprising administration of autologous mononuclear T regulatory cells isolated from adipose tissue into a patient, said cells administered in combination with an agent capable of suppressing TNF-alpha activity.
7. A method of immune modulation comprising: a) extracting a heterogeneous population of adipose derived cells containing a T regulatory and stem cell population therein; b) treating said heterogeneous population with one or more activators of stem cell proliferation; c) treating said heterogeneous population with one or more agents capable of enhancing Treg activation/expansion; and d) administering said heterogeneous population into a patient.
8. A method of immune modulation comprising: a) extracting a heterogeneous population of adipose derived cells containing a T regulatory and stem cell population therein; b) treating said heterogeneous population with one or more activators of stem cell proliferation; c) treating said heterogeneous population with one or more agents capable of enhancing Treg activation/expansion; and d) purifying said Treg populations and/or stem cell populations and administering into a patient depending on immune modulation desired.